Shifting the lines against central nervous system disorders

« A disruptive technology, which can be applied in the treatment of numerous conditions »

> Press releases 2017

Information on the total number of voting rights and shares (french only)
18/12/2017
Download PDF File (650 Ko)

End of stabilization period and implementation of a liquidity contract (french only)
18/12/2017
Download PDF File (917 Ko)

Theranexus files its registration document as part of its planned Initial Public Offering (IPO) on the Euronext Growth market in Paris
28/09/2017
Download PDF File (637 Ko)

Success of Theranexus' IPO on Euronext Growth in Paris
25/10/2017
Download PDF File (917 Ko)

Theranexus announces issuance of US patent covering its drug candidate THN102 for treatment of narcolepsy and Parkinson's disease
22/09/2017
Download PDF File (222 Ko)

Theranexus renforce son équipe de management avec l'arrivée de Thierry Lambert en tant que directeur financier
14/09/2017
Download PDF File (210 Ko)

Theranexus announces the nomination of Werner Rein as Chief Medical Officer (CMO)
29/08/2017
Download PDF File (93 Ko)

Theranexus annonce la publication d'un article scientifique évaluant le rôle des cellules non neuronales dans le traitement du système nerveux central
18/07/2017
Download PDF File (106 Ko)